Based on the aggregated intelligence of 165,000-plus investors participating in Motley Fool CAPS, the Fool's free investing community, health-care giant Abbott Labs (NYSE: ABT) has earned a respected four-star ranking.

With that in mind, let's take a closer look at Abbott's business, and see what CAPS investors are saying about the stock right now.

Abbott facts

Headquarters (Founded)

Abbott Park, Ill. (1888)

Market Cap

$74.1 billion

Industry

Pharmaceuticals

Trailing-12-Month Revenue

$31.7 billion

Management

CEO Miles White (since 1999)
CFO Thomas Freyman (since 2001)

Return on Equity (Average, Past 3 Years)

26.8%

Cash/Debt

$1.8 billion / $17.5 billion

Dividend Yield

3.7%

Competitors

Johnson & Johnson (NYSE: JNJ)
Boston Scientific (NYSE: BSX)

Sources: Capital IQ (a division of Standard & Poor's) and Motley Fool CAPS.

On CAPS, 95.5% of the 1,935 members who have rated Abbott believe the stock will outperform the S&P 500 going forward. These bulls include All-Star sehawk99, who is ranked in the top 5% of our community, and goldseth.

Just last week, sehawk99 tapped Abbott as an interesting income opportunity: 

Strong company. Well run. Nice dividend ... to help support the stock price. History of raising dividends. Nice income stream in the future.

Even with the 2008 patent loss on its blockbuster epilepsy drug Depakote, many in our community are still high on Abbott's long-term prospects. Abbott's workhorse, arthritis medication Humira, continues to see double-digit sales growth despite strong competition from the likes of Johnson & Johnson (NYSE: JNJ) (Remicade) and Amgen (Enbrel). Meanwhile, Abbott's new coronary stent Xience has outperformed Boston Scientific's Taxus -- the best-selling stent in the U.S. -- in clinical trials.

With Abbott shares down 10% year to date, CAPS members like goldseth think Abbott represents a rather healthy bargain:

Valuation, strong dividend yield/growth, strong cash flow. Considering the last year's market rally and current flirting with support/resistance levels, any S&P correction could result in allocation to safety of high yield stocks with strong balance sheets, cash flow and growth opportunities.

I believe the stock is undervalued due to Depakote patent loss and slowing Humira growth. [In my opinion], these concerns are more than offset by global expansion, strategic acquisitions, new indications for Humira, and the promising vascular lines.

What do you think about Abbott, or any other stock for that matter? If you want to retire rich, you need to put together the best portfolio you can. Owning exceptional stocks is a surefire way to secure your financial future, and on Motley Fool CAPS, thousands of investors are working every day to find them. CAPS is 100% free, so get started!